Tesamorelin
- Evidence
- Approved drug evidence
- Class
- GHRH analog
Tesamorelin belongs to the GHRH analog class. This library groups it under digestive & weight. Its source category is FDA-approved.
At a glance
| Compound class | GHRH analog |
|---|---|
| Associated brands | Egrifta SV |
| Body system | Digestive & weight |
| Use or research focus | HIV-associated lipodystrophy (visceral fat) |
| Regulatory status | FDA-approved |
| Source evidence rating | Approved drug evidence |
How does Tesamorelin work?
Stimulates endogenous GH release.
The source catalog maps this mechanism to Pituitary, Adipose / Fat. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
An approved medicine can still have contraindications, interactions, and serious adverse effects. The current prescribing label is the place to check product-specific warnings. A clinician should review your medical history and other medicines before treatment.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Tesamorelin?
Tesamorelin belongs to the GHRH analog class. This library groups it under digestive & weight. Its source category is FDA-approved. Its recorded use or research focus is: HIV-associated lipodystrophy (visceral fat).
Is Tesamorelin FDA-approved?
The catalog records: FDA-approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.
Where can I read the research?
The Citations tab contains 14 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for digestive & weight
Factual catalog fields and citation links are adapted from Superpower’s Tesamorelin guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Tesamorelin in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01anabolic and lipolyticdailymed.nlm.nih.gov
- 02largest trialdoi.org
- 03Egrifta WRdailymed.nlm.nih.gov
- 04extensiondoi.org
- 05adipose tissuedoi.org
- 06approvedaccessdata.fda.gov
- 07non-HIV populations with visceral adipositypubmed.ncbi.nlm.nih.gov
- 08HIV-associated non-alcoholic fatty liver diseasepubmed.ncbi.nlm.nih.gov
- 09reported a 15.2% VAT reductionpubmed.ncbi.nlm.nih.gov
- 10a treatment effect of approximately -15.4%pubmed.ncbi.nlm.nih.gov
- 11visceral fat returns toward baseline after discontinuationpubmed.ncbi.nlm.nih.gov
- 12no significant differences in fasting glucosepubmed.ncbi.nlm.nih.gov
- 13an HbA1c of 6.5% or higherdailymed.nlm.nih.gov
- 14resistance to DPP-IV degradationpubmed.ncbi.nlm.nih.gov